Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Care to explain how I’m twisting things, when I’m the one here pointing out the entire context and full quotes straight from the company and ceo lmao?
The company never stated “no RS”. That’s a fact. The stated opinion was that the ceo thinks $4 can be obtained without an RS. The same ceo who less than a week prior in a private email claimed he didn’t understand what an RS is. Lmao.
The company never stated the entire umbrella of JFHE was coming in here “within 6 months”. Fact. The quote was “6 months or more”.
You can’t dispute either of these things.
I’m not saying a RS will happen either, who knows. But in reality, it’s very likely. Every pump so far has failed to get this to even hold .01 cent, let alone the astronomical prospect of $4 per share without an RS. Not to mention it’s a fact that at some unknown point, 20 billion (yes you all read that correctly lol) is coming in here. 24 billion shares is insane. For now, just making it a point to get the other quotes and context correct since they’ve been purposely twisted for the pump narrative.
I won’t mind if it does dip more. I bought more today at the low and I’ll do it again. Like I mentioned, I had been in E*ZC from the early days and it was all talk. Just empty promises and unfulfilled potential and milestones, never had a single clinical trial underway and early on had given the hope to shareholders of govt funding, but none of it ever happened. This one isn’t just talk, they already have previous promising trial results, actually have some govt funding already secured and have stage 2/2b clinical trials coming later this year. The share structure is also very good for an otc. And most of all, the market cap is insanely low for a small bio with this progress and this much potential. Look at N*BO, 563 million market cap with similar share structure as this. They have progressed past various clinical trials too but do not yet have any major market approval of any kind or any approved drug on the market. I’m sure there’s much better comparisons as that one is just one I personally have a stake in, but come on, we’re talking about a market cap here of 394 thousand currently lol. Yes, just 394,000. Crazy. Imagine even a 50, or 100 mil market cap here and what share price that equates to.
They never said no RS. The ceo gave an opinion that he thought they could reach NASDAQ pps without needing to do an RS. Simply an opinion and means nothing. People love to twist statements. Just like the “whole company coming in here within 6 months” BS. The real quote was “6 months or more”. Meaning it could be anywhere from 6 months to possibly years.
Do you have any clue how crazy it is for a small bio with a good share structure, clinical trials already completed and stage 2/2b coming later this year, very real buyout or partnership scenarios and it’s sitting at this minuscule market cap? The market cap alone should be setting off buy alerts in peoples heads. The pps potential from this current level on the market cap alone for a clinical stage bio with govt funding and further progress this year into next is mind blowing.
I’m talking overall catalysts, not immediate short term “flipper” catalysts. The flipper catalyst would be pink current. And I’m sure I don’t need to point out overall catalysts for this. They’re known. But let’s be real, most here don’t have a clue about bio plays and they were clearly hoping for a quick flip. Why else be crying like this after a couple weeks?
Lmao imagine thinking that a bio companies biggest catalyst it could announce is a govt funding award. Do us all a favor and just sell and move on to something else.
Spoken like a true otc moron. Sell us your shares and good riddance.
Congrats on already being in the early running for stupidest post of the day.
Tell us you have no clue how bio plays work without actually telling us. Lmao.
The clinical trials are happening before end of the year. If those have good results as the company fully expects, it’s not going to take a “year or more” for this to explode in price. Not to mention this becomes a serious candidate for a big pharma partnership or buyout with those trial results. And that’s just a small part of their pipeline.
Nice update!
Same, grabbed more this morning. Makes up for missing out on some last week. As long as it remains in this range, it’s a no brainer to accumulate shares. Then again, when talking about the majority of otc traders, no brains kind of goes with the territory. Works out great for those of us that can see beyond a flip trade.
There’s so many dirty names involved in this. That’s why it’s not as simple as just taking ENZC back from Harry. There’s a handful of names here that would fully need cleaned out for this to even be worth the 3C’s bringing their assets back under it. Fully believe that it’s far easier for them to just move Adnexus and their assets into a new clean shell and start fresh.
The majority of otc traders know nothing about bio stocks and don’t care enough to learn. And most don’t have the patience to look beyond a flip or swing play. It is what it is, gives me more time to keep adding.
Beyond that, it’s going to be an even more interesting next 8-12 months.
Has this been mentioned in the E*Z* Discord yet? Was kicked from there awhile back for asking legitimate questions.
“Don't forget you sharing your illegal insider information that supposedly came directly from Chandra”
I was “focused up”. The above is literally part of what you stated. Which is false.
Since the limited info given out is basically only what they now potentially plan to do in regards to ENZC, that isn’t insider information, bc Chandra and the Cotropias no longer work for the company.
Nice day here today, managed to get an order filled at .0029 to add to the rest.
Also, great to see a CEO that responded quickly to a couple investors and confirmed that he is working on the required info to move back to pink current asap. I saw more people saying to contact him. I’d say now that we have that confirmation, let’s just back off and let him do his job. Rare to have an OTC CEO even reply to investors in the first place so let’s not over do it. But it’s a great sign and further proof this is a legitimate company moving in the right direction.
Pumping a stock even if it’s happening isn’t illegal. You spend your entire time on this site doing the exact opposite, bashing everything bc you’re bitter that you miss out. Hypocrite.
Have they mentioned a timeframe for getting pink current? After that and .01 being easily achieved, they should apply for the QB tier and that’s all it will take for a steady move up as the stage 2 trails commence later this year.
E*ZC had to eventually dilute because they had secured no funding at any point.
Even if there’s some dilution here, the funding is legit and already secured for the next step, so it should be minimal. Since their pipeline clearly shows promise and is much further along than E*ZC’s was, further funding is very likely as well.
Keep in mind this o/s is about 1/4 what E*ZC’s was and the total a/s here is about 1/2. Much better share structure.
Remember how the other one traded back in late 2020, took a few months for everyone to catch on. Went out of trips to over half a penny, then consolidated for awhile before breaking over .01. From that point we’d move up multiple pennies at a time. Today was a given after the crazy day yesterday.
Agreed
The lower they take it the more I’m buying. Makes up for almost missing out on this had it not dipped at all, and also for my big buy yesterday morning I regretted not pulling the trigger on. Let those that aren’t familiar with bio stocks or see the bigger picture move on!
I believe so if things progress as they should. They are going to need to get current and once past .01, they should also take the steps to move up to OTCQB. That will help further legitimize this and take the needed steps to move beyond the standard OTC.
The thing that continues to worry me is this.
Taking back control of ENZC by the 3C’s from Harry will simply put them right back where they were for 3 1/2 years since the merger.
That really does no good. They need to remove Harry completely, get SS gone as well as the other Z’s.
No progress could be made for the entire 3 1/2 years bc of either Harry’s meddling or his skeletons in the closet. What makes anyone think that just getting control back with CC in charge is going to change anything and allow the progress thats been hitting a roadblock every step of the way before.
For this to move forward, they need to not only take back control of ENZC which is a major hurdle itself, but the bigger hurdle is going to be cleaning house of the entire scummy crew that’s involved in this now (Harry, Steve, Kelli, the other Z family). How do they possibly remove all of those names from any future involvement here, so they can move forward with no more skeletons in the closet or potential problems?!
That’s why I continue to believe that it’s far easier for them to continue forward with Adnexus under a new shell ticker, which can be had clean for under $500,000. No one’s gonna tell me the process to not only take back ENZC, but also remove all the problem names noted above from any aspect of this, is going to cost them less than $500,000 in legal proceedings and more importantly the time wasted to carry out that whole process. Chandra teased Adnexus having its own stock symbol coming soon, so why would he do that if they were going the other route instead back into ENZC? And for those thinking maybe they’d be merging back into this later from a Adnexus ticker, that makes no sense bc you’re then taking on this 4 bil o/s as well when you already would have a new clean shell with a likely better share structure to start fresh.
Beautiful dip buy chances today for those that see the bigger picture here. Grabbed some more. Love a good bio stock.
And this one actually has govt funding approval and will be in stage 2/2b clinical trials later this year. E*ZC only had hoped to get funding and had not even begun any clinical trials. We still had a huge following over there and it ended pretty badly recently, hopefully most of the group there finds their way over here. This could become what we had hoped to see there for 3 1/2 years that didn’t pan out.
Take a good look at the dd. Still very early.
You weren’t paying attention, the profit taking sell off happened from the hod midday to where it closed. Though I wouldn’t be upset if more profit taking happens, I’d love another dip. This feels, for me at least, like getting a second chance at 2020 early E*Z* again before it took off. I could see a similar following develop here. But this one’s got actual substance, phase 2 trials coming and govt funding secured. It’s not just hype and empty promises like occured over there.
Agreed, that was basically my extreme low ball estimate by year end. Potential is far beyond that.
I’d say a low ball market cap for this by end of the year should be 75 million. Around .10 cents. Most will prob argue that a 75 mil market cap by year end is way too low and that’s prob true. Also, that’s very low compare to other otc bios I’ve seen in the hundreds of millions market cap with far less progress and no govt funding at all. Also with worse share structures. In this market who really knows, but even at that mc I think most could agree this would be way undervalued.
The value of a bio company is well beyond just what funding they’ve secured so far.
A deal for a partnership or a complete buyout would surely be possibilities later this year.
A 200 million market cap would be about .25 cents per share. It won’t reach that overnight or maybe even until late this year, but with stage 2 trials coming before year end and govt funding, it should steadily make its way there eventually. I’ve been in one otc bio specifically with more than a 200 mil market cap that never had govt funding and never even started a single clinical trial.
This also will become a buyout target for big pharma as well and is prob already on their radar, maybe waiting for stage 2b results.
Same, gets better the more dd I do. Really kicking myself for not pulling the trigger on a larger buy order I had ready to go around 1030am today.
And still would be way undervalued at .09, that’s (ballparking in my head) only about a 72 million market cap. A stage 2 clinical trial bio with govt funding on the low end should be around a 200 mil market cap.
For sure. Guaranteed Big Pharma already has this on their radar, especially with the govt funding now in place and phase 2 trials coming.